Plato Investment Management Ltd Invests $1.73 Million in Becton, Dickinson and Company $BDX

Posted by Stanley Muller on Aug 18th, 2026

Plato Investment Management Ltd purchased a new stake in Becton, Dickinson and Company (NYSE:BDX – Free Report) during the 2nd quarter, Holdings Channel.com reports. The fund purchased 11,485 shares of the medical instruments supplier’s stock, valued at approximately $1,728,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Imprint Wealth LLC acquired a new stake in Becton, Dickinson and Company during the 3rd quarter worth approximately $25,000. SHP Wealth Management acquired a new position in shares of Becton, Dickinson and Company in the fourth quarter valued at approximately $26,000. Meeder Asset Management Inc. raised its stake in shares of Becton, Dickinson and Company by 152.2% during the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 102 shares during the last quarter. Main Street Group LTD purchased a new stake in shares of Becton, Dickinson and Company during the first quarter worth approximately $29,000. Finally, Bell Investment Advisors Inc acquired a new stake in shares of Becton, Dickinson and Company during the second quarter worth $29,000. 86.97% of the stock is owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Trading Down 0.6%

NYSE:BDX opened at $182.39 on Tuesday. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $187.35. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. The stock has a fifty day moving average price of $158.48 and a two-hundred day moving average price of $161.26. The stock has a market capitalization of $50.26 billion, a price-to-earnings ratio of 54.94, a PEG ratio of 12.93 and a beta of 0.19.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same period in the previous year, the firm earned $3.68 EPS. The business’s revenue was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, sell-side analysts anticipate that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be issued a dividend of $1.05 per share. The ex-dividend date of this dividend is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.3%. Becton, Dickinson and Company’s payout ratio is currently 126.51%.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on BDX shares. Wells Fargo & Company boosted their price objective on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an “equal weight” rating in a research note on Friday, August 7th. Evercore set a $180.00 target price on shares of Becton, Dickinson and Company in a research note on Monday, July 6th. Barclays lifted their target price on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a report on Monday, May 11th. Piper Sandler increased their price target on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a “neutral” rating in a report on Friday, August 7th. Finally, UBS Group assumed coverage on shares of Becton, Dickinson and Company in a research report on Tuesday, July 28th. They issued a “buy” rating and a $190.00 price objective for the company. Eight equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $185.67.

Get Our Latest Analysis on Becton, Dickinson and Company

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP Roland Goette sold 2,438 shares of the company’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the transaction, the executive vice president directly owned 14,856 shares in the company, valued at approximately $2,686,559.04. This represents a 14.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Michael David Garrison sold 1,100 shares of Becton, Dickinson and Company stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total transaction of $160,226.00. Following the sale, the executive vice president owned 13,172 shares of the company’s stock, valued at approximately $1,918,633.52. The trade was a 7.71% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 11,779 shares of company stock worth $1,974,669. 0.40% of the stock is owned by company insiders.

Becton, Dickinson and Company Company Profile

(Free Report)

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.